NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AT, BE, BG, HR, CY, CZ, DK, EE, FR, FI, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SK, SI, CH, ES, SE, GB, IE, NO, CH”]
Robert Shahverdyan (Hamburg, Germany), Matteo Tozzi (Varese, Italy), Alexandros Mallios (Paris, France), Ounali Jaffer (London, UK) and Narayan Karunanithy (London, UK) each give their take on the 36-month results of the IN.PACT AV Access trial, which were presented for the first time at the 2022 Charing Cross (CX) International Symposium (26–28 April, London, UK).
End-stage kidney disease (ESKD) patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) remained intervention-free for longer than those who received standard percutaneous transluminal angioplasty (PTA), according to the findings. The data also showed a target-lesion primary patency (TLPP) rate of 43.1% in the DCB group, compared to 28.6% in the PTA group at the 36-month timepoint. In addition, there was a 21.3% reduction in reinterventions associated with DCB use, with 255 reinterventions to maintain TLPP being required through 36 months in the DCB group versus 324 in the PTA group.
This video is sponsored by Medtronic.
[/geoip-content]
